Journal article

Targeting primary human Ph( ) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies.

Paul Mitchell, Fook-Thean Lee, Cathrine Hall, Angela Rigopoulos, Fiona E Smyth, Anne-Marie Hekman, Gijs M van Schijndel, Ray Powles, Martin W Brechbiel, Andrew M Scott

J Nucl Med | Published : 2003

Abstract

UNLABELLED: The Philadelphia chromosome translocation (Ph(+)) confers a poor prognosis in patients with acute lymphocytic leukemia (ALL). CD19 is highly expressed (CD19(+)) on ALL cells and is an attractive target for antibody-based therapies. CLB-CD19 is an IgG1kappa murine monoclonal antibody (mAb) directed against an epitope on the CD19 antigen. METHODS: Radiolabeled CLB-CD19 antibody was evaluated for targeting ALL in a severe combined immunodeficient (SCID) mouse model engrafted with primary human leukemia cells. Lodgment of CD19(+) ALL cells in spleen and liver was confirmed using immunohistochemistry analyses. Circulating CD19(+) ALL cells in blood were also detected by flow cytometry..

View full abstract